Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Katie Ertelt"'
Autor:
Alison Stopeck, Paulette Mattson, Michael Chisamore, Richard D. Huhn, B Ma, Mark T. Uhlik, Jeremy R. Graff, R Prathikanti, Nandita Bose, Michele Gargano, Katie Ertelt, Steven J. O'Day, Jamie Lowe, Nadine Ottoson
Publikováno v:
Cancer Research. 78:OT1-01
By blocking the interaction of PD-L1 with PD-1, immune checkpoint inhibitors (CPI) can unleash specific, anti-cancer killing function of activated cytotoxic T cells in patients (pts) for whom there is evidence of an ongoing anti-cancer immune respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a676258bb97b62a37b60523f9eebe823
https://doi.org/10.1158/1538-7445.sabcs17-ot1-01-04
https://doi.org/10.1158/1538-7445.sabcs17-ot1-01-04
Autor:
Richard D. Huhn, Mable Ma, Michael Chisamore, Richard Walsh, Steven J. O'Day, Nandita Bose, Jeremy R. Graff, Steven M. Leonardo, Bruno Osterwalder, Michele Gargano, Paulette Mattson, Mark Uhlik, Radha Prathikanti, Ben J. Harrison, Jamie Lowe, Katie Ertelt, Xiaohong Qiu, Nadine Ottoson
Publikováno v:
Molecular Cancer Therapeutics. 17:LB-A31
Imprime PGG (Imprime) is a novel immunotherapeutic that acts as a non-self danger signal to activate the innate immune system and coordinate an adaptive immune system response. In multiple preclinical tumor models, Imprime significantly enhances anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e1ddeb837044cf114997937b4d6541d
https://doi.org/10.1158/1535-7163.targ-17-lb-a31
https://doi.org/10.1158/1535-7163.targ-17-lb-a31
Autor:
Mark T. Uhlik, Michael E. Danielson, Nadine R. Ottoson, Nandita Bose, Jamie Lowe, Jeremy R. Graff, Richard D. Huhn, Ben Harrison, Xiaohong Qiu, Steven M. Leonardo, Jose Iglesias, Myra L. Patchen, Anissa S.H. Chan, Kyle S. Michel, M. Ma, Keith B. Gorden, Richard Walsh, Katie Ertelt, A. Bykowski Jonas
Publikováno v:
European Journal of Cancer. 69:S106-S107
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7d2aa074c715ae052c2b188168d97a0
https://doi.org/10.1016/s0959-8049(16)32915-x
https://doi.org/10.1016/s0959-8049(16)32915-x
Autor:
Adria Jonas, Keith B. Gorden, Mark T. Uhlik, Takashi Kangas, Nadine Ottosson, Nandita Bose, Richard Walsh, Jamie Lowe, Steven M. Leonardo, Ross B. Fulton, Richard D. Huhn, Benjamin Harrison, Xiaohong Qiu, Jeremy R. Graff, Katie Ertelt
Publikováno v:
Cancer Research. 77:3688-3688
Immune checkpoint inhibitors (CPI) have shown compelling clinical efficacy in multiple tumor types, though only in a minority of treated patients. Significant research and clinical development are focused on expanding CPI efficacy. Imprime PGG is a n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7afcc41d283dd06d3ef0b2102278543b
https://doi.org/10.1158/1538-7445.am2017-3688
https://doi.org/10.1158/1538-7445.am2017-3688
Autor:
Jamie Lowe, Michael Chisamore, Mark T. Uhlik, Nandita Bose, Paulette Mattson, Nadine Ottoson, Jose Iglesias, Jeremy R. Graff, Richard D. Huhn, Katie Ertelt, Bo Ma, Deb Kedrowski, Radha Prathikanti
Publikováno v:
Journal of Clinical Oncology. 35:TPS3105-TPS3105
TPS3105 Background: Imprime PGG (Imprime) is a Pathogen- Associated Molecular Pattern that enhances innate immune cell killing, counteracts immune suppression and triggers activation and maturation of antigen presenting cells. Imprime’s ability to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af6bef6f29c82cbe2c72b7555091f952
https://doi.org/10.1200/jco.2017.35.15_suppl.tps3105
https://doi.org/10.1200/jco.2017.35.15_suppl.tps3105
Autor:
Jamie Lowe, Ben Harrison, Kathryn A. Fraser, Richard Walsh, Nandita Bose, Mark T. Uhlik, Anissa S.H. Chan, Nadine Ottoson, Blaine Rathmann, Jeremy R. Graff, Adria Jonas, Richard D. Huhn, Steven M. Leonardo, Lindsay R. Wurst, Ross B. Fulton, Jose Iglesias, Mark A. Matson, Katie Ertelt, Takashi O Kangas, Keith B. Gorden, Xiaohong Qiu
Publikováno v:
Cancer Immunology Research. 4:B008-B008
Imprime PGG (Imprime), in combination with both tumor-targeting and anti-angiogenic antibodies, has shown promising efficacy in multiple phase 2 clinical trials. In numerous pre-clinical in vivo tumor models, Imprime also enhances the efficacy of imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbda6cdaf06ea67270213cf9ae5247f6
https://doi.org/10.1158/2326-6066.imm2016-b008
https://doi.org/10.1158/2326-6066.imm2016-b008
Autor:
Nadine Ottoson, Steven M. Leonardo, Keith B. Gorden, Adria Jonas, Peter Maimonis, Katie Ertelt, Ben Harrison, Anissa S.H. Chan, Nandita Bose, Xiaohong Qiu, Lindsay R. Wurst
Publikováno v:
Cancer Immunology Research. 4:A014-A014
Imprime PGG (Imprime), a soluble yeast 1,3/1,6 β-glucan, is being developed as a novel cancer immunotherapy in conjunction with anti-tumor antibodies in several cancers. Randomized Phase 2 clinical trials of Imprime in the 1st-line treatment of stag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d7e496df1dfc00e893b20c229fa7038
https://doi.org/10.1158/2326-6074.cricimteatiaacr15-a014
https://doi.org/10.1158/2326-6074.cricimteatiaacr15-a014
Autor:
Nadine Ottoson, Adria Jonas, Xiaohong Qiu, Richard Walsh, Nandita Bose, Diane McMurray, Lindsay R. Wurst, Steven M. Leonardo, Ben Harrison, Peter Maimonis, Katie Ertelt
Publikováno v:
Cancer Immunology Research. 3:A08-A08
Imprime PGG (Imprime) is a yeast-derived beta-1,3/1,6 glucan that binds complement receptor 3 (CR3) on innate immune cells and enables these cells to exert anti-tumor activity against tumor cells that have been opsonized by iC3b following targeting b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b87b5d2fa78d8e54e71327993d24ac5a
https://doi.org/10.1158/2326-6074.tumimm14-a08
https://doi.org/10.1158/2326-6074.tumimm14-a08
Autor:
Jamie Lowe, Parvis Sadjadian, Myra L. Patchen, Katie Ertelt, Diane McMurray, Richard D. Huhn, Anissa S.H. Chan, Keith B. Gorden, Paulette Mattson, Nandita Bose, Michele Gargano, Michael Thomas, Mary A. Antonysamy, Adria Jonas, Nadine Ottoson, Xiaohong Qui, Lindsay R. Wurst, Steven M. Leonardo, Richard Walsh, Folker Schneller
Publikováno v:
Journal of Clinical Oncology. 32:3045-3045
3045 Background: Imprime PGG (IPGG) is a yeast-derived β-1,3/1,6 glucan that primes innate immune cells to kill antibody-targeted cancer cells via a complement receptor 3 (CR3)-dependent mechanism. In humans, naturally occurring anti-β-glucan antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc14256abc69af936b5f20df56c54ad1
https://doi.org/10.1200/jco.2014.32.15_suppl.3045
https://doi.org/10.1200/jco.2014.32.15_suppl.3045
Autor:
Mary Antonysamy, Nandita Bose, Anissa Chan, Katie Ertelt, Keith Gorden, William Grossman, Richard Huhn, Adria Jonas, Steven Leonardo, Jamie Lowe, Paulette Mattson, Diane McMurray, Mariana Nelson, Nadine Ottoson, Myra Patchen, Xiaohong Qiu, Blaine Rathman, Richard Walsh, Lindsay Wurst, Yumi Yokoyama
Publikováno v:
The Journal of Immunology. 192:73.9-73.9
The innate immune response to Imprime PGG® (Imprime PGG) is being leveraged to develop a novel cancer immunotherapy in conjunction with anti-tumor monoclonal antibodies. Previous research has demonstrated the presence of endogenous anti-β-glucan an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67f7ff51705de0cf23b92f8e0deac4b1
https://doi.org/10.4049/jimmunol.192.supp.73.9
https://doi.org/10.4049/jimmunol.192.supp.73.9